**Supplementary Table S5: Univariable cox regression models for EGFR-TKI vs. chemotherapy.**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | HR (progression) | HR (death) |
|  | Group\*  | no. of patients | HR | 95% CI | p-value | no. of patients | HR | 95% CI | p-value | HR |
| 1st Line | **1** | 79 | **0.53** | **0.30 - 0.93** | **0.028** | 79 | 0.97 | 0.54 - 1.75 | 0.929 | 0.97 |
| 2 | 55 | 1.29 | 0.64 - 2.61 | 0.473 | 55 | 0.62 | 0.27 - 1.41 | 0.255 | 0.62 |
| 3 | 84 | 0.71 | 0.42 - 1.18 | 0.187 | 84 | 0.65 | 0.37 - 1.14 | 0.131 | 0.65 |
|  | group  | no. of treatments | HR | 95% CI | p-value | no. of treatments | HR | 95% CI | p-value | HR |
| All lines | 1 | 143 | **0.54** | **0.35 - 0.81** | **0.003** |  |  |  |  |  |
| 2 | 97 | 1.27 | 0.77 - 2.09 | 0.349 |  |  |  |  |  |
| 3 | 172 | **0.67** | **0.47 - 0.95** | **0.025** |  |  |  |  |  |

\*1,uncommon EGFR mutations; 2, Exon 20 insertions; 3, very rare EGFR mutations